<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02256085</url>
  </required_header>
  <id_info>
    <org_study_id>6818</org_study_id>
    <nct_id>NCT02256085</nct_id>
  </id_info>
  <brief_title>Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)</brief_title>
  <official_title>Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City University of New York, School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial (RCT) on the efficacy of repetitive Transcranial&#xD;
      Magnetic Stimulation (rTMS) in the treatment of Depersonalization Disorder (DPD). TMS applies&#xD;
      a magnetic field to the brain for a brief period of time. TMS is a procedure that involves 30&#xD;
      minute-long daily sessions every weekday for a series of weeks. The investigators are testing&#xD;
      whether TMS can treat Depersonalization Disorder (DPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a research trial of an outpatient, non-medication, non-invasive investigational&#xD;
      treatment called Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive tool for the&#xD;
      study of the human brain that has been approved by the FDA for use in depression, but it is&#xD;
      also being investigated as a potential therapeutic agent for other symptoms, such as those&#xD;
      seen in Depersonalization Disorder (DPD).&#xD;
&#xD;
      TMS applies a magnetic field to the brain for a brief period of time. TMS is a procedure that&#xD;
      involves 30 minute-long daily sessions every weekday for a series of weeks. The investigators&#xD;
      are testing whether TMS can treat Depersonalization Disorder (DPD).&#xD;
&#xD;
      In this trial, 32 adult outpatients with DPD, that have been only partially responsive to&#xD;
      conventional therapies, will be treated with active or sham low frequency (1 Hz) rTMS applied&#xD;
      to the right temporo-parietal junction (TPJ) daily for up to six weeks.&#xD;
&#xD;
      DPD symptoms will be monitored through weekly self-report questionnaires as well clinical&#xD;
      ratings with a doctor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cambridge Depersonalization Scale (CDS)</measure>
    <time_frame>Change from baseline after 6 weeks of active rTMS</time_frame>
    <description>The outcome of subjects randomized to active rTMS in phase 1 will be assessed as the change from baseline after 6 weeks of daily rTMS (week 6 assessment). Subjects randomized to receive sham in phase 1 will be assessed at baseline and week 6, but the primary method of assessing improvement will be the change between the baseline and week 12 scores (i.e. after receiving 6 weeks of active rTMS).&#xD;
Scale item number: 29 Item score range: Frequency: 0 - 4, Duration: 0-5 Minimum CDS score: 0 Maximum CDS score: 261&#xD;
Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement (assessed by CGI-S)</measure>
    <time_frame>Change from baseline after 6 weeks of active rTMS</time_frame>
    <description>The outcome of subjects randomized to active rTMS in phase 1 will be assessed as the change from baseline after 6 weeks of daily rTMS (week 6 assessment). Subjects randomized to receive sham in phase 1 will be assessed at baseline and week 6, but the primary method of assessing improvement will be the change between the baseline and week 12 scores (i.e. after receiving 6 weeks of active rTMS).&#xD;
Minimum CGI-S score: 1 Maximum CGI-S score: 7&#xD;
Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.&#xD;
Patients will be classified as responders with a CGI-S = 1 or 2; and partial responders CGI-S = 3.&#xD;
= Normal, not at all ill&#xD;
= Borderline mentally ill&#xD;
= Mildly ill&#xD;
= Moderately ill&#xD;
= Markedly ill&#xD;
= Severely ill&#xD;
= Among the most extremely ill patients</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Depersonalization Disorder</condition>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Daily rTMS with Sham coil&#xD;
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily rTMS with Active coil&#xD;
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Daily rTMS with Active coil&#xD;
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Daily rTMS with Active coil</intervention_name>
    <description>rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks</description>
    <arm_group_label>Active rTMS</arm_group_label>
    <other_name>Magstim, Magstim Rapid, Magstim Rapid2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Daily rTMS with Sham coil</intervention_name>
    <description>rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks</description>
    <arm_group_label>Sham rTMS</arm_group_label>
    <other_name>Magstim, Magstim Rapid, Magstim Rapid2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Open Label Daily rTMS with Active coil</intervention_name>
    <description>rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks</description>
    <arm_group_label>Open Active rTMS</arm_group_label>
    <other_name>Magstim, Magstim Rapid, Magstim Rapid2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female outpatients, 18 to 70 years of age.&#xD;
&#xD;
          -  Primary diagnosis of Depersonalization Disorder.&#xD;
&#xD;
          -  Duration of the index episode of at least a year.&#xD;
&#xD;
          -  Patients currently on DPD medication must be at the same stable dose(s) at least 2&#xD;
             months and be to continue at the same dose(s) through the duration of the study.&#xD;
&#xD;
          -  Patients must continue to be under the care of their treating psychiatrist who will be&#xD;
             writing prescriptions for concomitant medications through the duration of the study.&#xD;
&#xD;
          -  Capable and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals diagnosed with current Major Depressive Disorder or Panic Disorder.&#xD;
&#xD;
          -  Individuals diagnosed with the following conditions: Bipolar Disorder (lifetime), any&#xD;
             Psychotic Disorder (lifetime), History of substance abuse or dependence within the&#xD;
             past yea (except nicotine and caffeine).&#xD;
&#xD;
          -  Individuals with a neurological disorder including, but not limited to: brain lesion;&#xD;
             history of seizures; history of cerebrovascular accident; history of stroke; TIA,&#xD;
             cerebral aneurysm, Dementia; Parkinson's Disease; Huntington's chorea; Multiple&#xD;
             Sclerosis.&#xD;
&#xD;
          -  Increased risk of seizure for any reason, including prior head trauma with loss of&#xD;
             consciousness for 5 minutes or more&#xD;
&#xD;
          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable&#xD;
             cardiac disease.&#xD;
&#xD;
          -  Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants,&#xD;
             or electrodes) or any other metal object within or near the head, excluding the mouth,&#xD;
             that cannot be safely removed.&#xD;
&#xD;
          -  History of treatment with rTMS therapy for any disorder.&#xD;
&#xD;
          -  If participating in psychotherapy, must have been in stable treatment for at least&#xD;
             three months prior to entry into the study, with no anticipation of change in&#xD;
             frequency of therapeutic sessions, or the therapeutic focus over the duration of the&#xD;
             rTMS trial.&#xD;
&#xD;
          -  Known or suspected pregnancy.&#xD;
&#xD;
          -  Women who are breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Mantovani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUNY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Javitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sophie Davis School of Biomedical Education, City University of New York (CUNY)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute, Experimental Therapeutics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://columbiapsychiatry.org/</url>
    <description>Department of Psychiatry, Columbia University Medical Center</description>
  </link>
  <link>
    <url>http://www.ccny.cuny.edu/sophiedavis/physpharmandneuro.cfm</url>
    <description>Sophie Davis School of Biomedical Education, City University of New York (CUNY)</description>
  </link>
  <link>
    <url>http://www.nimh.nih.gov/index.shtml</url>
    <description>National Institute of Mental Health</description>
  </link>
  <reference>
    <citation>Blanke O, Mohr C, Michel CM, Pascual-Leone A, Brugger P, Seeck M, Landis T, Thut G. Linking out-of-body experience and self processing to mental own-body imagery at the temporoparietal junction. J Neurosci. 2005 Jan 19;25(3):550-7. doi: 10.1523/JNEUROSCI.2612-04.2005.</citation>
    <PMID>15659590</PMID>
  </reference>
  <reference>
    <citation>Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology. 1997 May;48(5):1398-403. doi: 10.1212/wnl.48.5.1398.</citation>
    <PMID>9153480</PMID>
  </reference>
  <reference>
    <citation>Hunter EC, Baker D, Phillips ML, Sierra M, David AS. Cognitive-behaviour therapy for depersonalisation disorder: an open study. Behav Res Ther. 2005 Sep;43(9):1121-30. doi: 10.1016/j.brat.2004.08.003.</citation>
    <PMID>16005701</PMID>
  </reference>
  <reference>
    <citation>Jimenez-Genchi AM. Repetitive transcranial magnetic stimulation improves depersonalization: a case report. CNS Spectr. 2004 May;9(5):375-6. doi: 10.1017/s1092852900009366.</citation>
    <PMID>15115950</PMID>
  </reference>
  <reference>
    <citation>Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol. 2003 Mar;17(1):103-5. doi: 10.1177/0269881103017001712.</citation>
    <PMID>12680746</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Guralnik O, Hazlett EA, Spiegel-Cohen J, Hollander E, Buchsbaum MS. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry. 2000 Nov;157(11):1782-8. doi: 10.1176/appi.ajp.157.11.1782.</citation>
    <PMID>11058475</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry. 2004 Jul;185:31-6. doi: 10.1192/bjp.185.1.31.</citation>
    <PMID>15231553</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol. 2005 Jun;25(3):267-70. doi: 10.1097/01.jcp.0000162803.61700.4f.</citation>
    <PMID>15876908</PMID>
  </reference>
  <reference>
    <citation>Simeon D. Depersonalisation disorder: a contemporary overview. CNS Drugs. 2004;18(6):343-54. doi: 10.2165/00023210-200418060-00002.</citation>
    <PMID>15089102</PMID>
  </reference>
  <reference>
    <citation>Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16. doi: 10.1016/s0168-5597(97)00096-8.</citation>
    <PMID>9474057</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14.</citation>
    <PMID>19833552</PMID>
  </reference>
  <reference>
    <citation>Christopeit M, Simeon D, Urban N, Gowatsky J, Lisanby SH, Mantovani A. Effects of repetitive transcranial magnetic stimulation (rTMS) on specific symptom clusters in depersonalization disorder (DPD). Brain Stimul. 2014 Jan-Feb;7(1):141-3. doi: 10.1016/j.brs.2013.07.006. Epub 2013 Aug 6. No abstract available.</citation>
    <PMID>23941986</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dissociative</keyword>
  <keyword>Dissociation</keyword>
  <keyword>Depersonalization</keyword>
  <keyword>Depersonalization Disorder</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>TMS</keyword>
  <keyword>DPD</keyword>
  <keyword>rTMS</keyword>
  <keyword>Behavioral Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depersonalization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02256085
org study id: 6818
nct id: NCT02256085
lead sponsor: 
collaborator: 
has dmc: No
This is a randomized controlled trial (RCT) on the efficacy of repetitive Transcranial
      Magnetic Stimulation (rTMS) in the treatment of Depersonalization Disorder (DPD). TMS applies
      a magnetic field to the brain for a brief period of time. TMS is a procedure that involves 30
      minute-long daily sessions every weekday for a series of weeks. The investigators are testing
      whether TMS can treat Depersonalization Disorder (DPD).
This study is a research trial of an outpatient, non-medication, non-invasive investigational
      treatment called Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive tool for the
      study of the human brain that has been approved by the FDA for use in depression, but it is
      also being investigated as a potential therapeutic agent for other symptoms, such as those
      seen in Depersonalization Disorder (DPD).

      TMS applies a magnetic field to the brain for a brief period of time. TMS is a procedure that
      involves 30 minute-long daily sessions every weekday for a series of weeks. The investigators
      are testing whether TMS can treat Depersonalization Disorder (DPD).

      In this trial, 32 adult outpatients with DPD, that have been only partially responsive to
      conventional therapies, will be treated with active or sham low frequency (1 Hz) rTMS applied
      to the right temporo-parietal junction (TPJ) daily for up to six weeks.

      DPD symptoms will be monitored through weekly self-report questionnaires as well clinical
      ratings with a doctor.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: Triple (Participant, Investigator, Outcomes Assessor)
measure: Cambridge Depersonalization Scale (CDS)
time frame: Change from baseline after 6 weeks of active rTMS
description: The outcome of subjects randomized to active rTMS in phase 1 will be assessed as the change from baseline after 6 weeks of daily rTMS (week 6 assessment). Subjects randomized to receive sham in phase 1 will be assessed at baseline and week 6, but the primary method of assessing improvement will be the change between the baseline and week 12 scores (i.e. after receiving 6 weeks of active rTMS).
Scale item number: 29 Item score range: Frequency: 0 - 4, Duration: 0-5 Minimum CDS score: 0 Maximum CDS score: 261
Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.
measure: Clinical Improvement (assessed by CGI-S)
time frame: Change from baseline after 6 weeks of active rTMS
description: The outcome of subjects randomized to active rTMS in phase 1 will be assessed as the change from baseline after 6 weeks of daily rTMS (week 6 assessment). Subjects randomized to receive sham in phase 1 will be assessed at baseline and week 6, but the primary method of assessing improvement will be the change between the baseline and week 12 scores (i.e. after receiving 6 weeks of active rTMS).
Minimum CGI-S score: 1 Maximum CGI-S score: 7
Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.
Patients will be classified as responders with a CGI-S = 1 or 2; and partial responders CGI-S = 3.
= Normal, not at all ill
= Borderline mentally ill
= Mildly ill
= Moderately ill
= Markedly ill
= Severely ill
= Among the most extremely ill patients
arm group label: Sham rTMS
arm group type: Sham Comparator
description: Daily rTMS with Sham coil
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil
arm group label: Active rTMS
arm group type: Experimental
description: Daily rTMS with Active coil
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil
arm group label: Open Active rTMS
arm group type: Experimental
description: Open Label Daily rTMS with Active coil
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil
intervention type: Device
intervention name: Daily rTMS with Active coil
description: rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
arm group label: Active rTMS
other name: Magstim, Magstim Rapid, Magstim Rapid2
intervention type: Device
intervention name: Daily rTMS with Sham coil
description: rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
arm group label: Sham rTMS
other name: Magstim, Magstim Rapid, Magstim Rapid2
intervention type: Device
intervention name: Open Label Daily rTMS with Active coil
description: rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
arm group label: Open Active rTMS
other name: Magstim, Magstim Rapid, Magstim Rapid2
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Antonio Mantovani, MD, PhD
role: Principal Investigator
affiliation: CUNY
last name: Daniel Javitt, MD, PhD
role: Principal Investigator
affiliation: New York State Psychiatric Institute
facility: 
facility: 
country: United States
url: http://columbiapsychiatry.org/
description: Department of Psychiatry, Columbia University Medical Center
url: http://www.ccny.cuny.edu/sophiedavis/physpharmandneuro.cfm
description: Sophie Davis School of Biomedical Education, City University of New York (CUNY)
url: http://www.nimh.nih.gov/index.shtml
description: National Institute of Mental Health
citation: Blanke O, Mohr C, Michel CM, Pascual-Leone A, Brugger P, Seeck M, Landis T, Thut G. Linking out-of-body experience and self processing to mental own-body imagery at the temporoparietal junction. J Neurosci. 2005 Jan 19;25(3):550-7. doi: 10.1523/JNEUROSCI.2612-04.2005.
PMID: 15659590
citation: Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology. 1997 May;48(5):1398-403. doi: 10.1212/wnl.48.5.1398.
PMID: 9153480
citation: Hunter EC, Baker D, Phillips ML, Sierra M, David AS. Cognitive-behaviour therapy for depersonalisation disorder: an open study. Behav Res Ther. 2005 Sep;43(9):1121-30. doi: 10.1016/j.brat.2004.08.003.
PMID: 16005701
citation: Jimenez-Genchi AM. Repetitive transcranial magnetic stimulation improves depersonalization: a case report. CNS Spectr. 2004 May;9(5):375-6. doi: 10.1017/s1092852900009366.
PMID: 15115950
citation: Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol. 2003 Mar;17(1):103-5. doi: 10.1177/0269881103017001712.
PMID: 12680746
citation: Simeon D, Guralnik O, Hazlett EA, Spiegel-Cohen J, Hollander E, Buchsbaum MS. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry. 2000 Nov;157(11):1782-8. doi: 10.1176/appi.ajp.157.11.1782.
PMID: 11058475
citation: Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry. 2004 Jul;185:31-6. doi: 10.1192/bjp.185.1.31.
PMID: 15231553
citation: Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol. 2005 Jun;25(3):267-70. doi: 10.1097/01.jcp.0000162803.61700.4f.
PMID: 15876908
citation: Simeon D. Depersonalisation disorder: a contemporary overview. CNS Drugs. 2004;18(6):343-54. doi: 10.2165/00023210-200418060-00002.
PMID: 15089102
citation: Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16. doi: 10.1016/s0168-5597(97)00096-8.
PMID: 9474057
citation: Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14.
PMID: 19833552
citation: Christopeit M, Simeon D, Urban N, Gowatsky J, Lisanby SH, Mantovani A. Effects of repetitive transcranial magnetic stimulation (rTMS) on specific symptom clusters in depersonalization disorder (DPD). Brain Stimul. 2014 Jan-Feb;7(1):141-3. doi: 10.1016/j.brs.2013.07.006. Epub 2013 Aug 6. No abstract available.
PMID: 23941986
responsible party type: Sponsor
mesh term: Depersonalization